Review ArticleAtrial Fibrillation in Hypertrophic Cardiomyopathy: Evidence-based Review About Mechanism, Complications and ManagementArunachalam, Karuppiah MD*; Maan, Abhishek MD†; Chu, Antony MD*Author Information From the *Division of Cardiology, The Warren Alpert Medical School of Brown University, Providence, Rhode Island †Department of Cardiology, Massachusetts General Hospital, Boston, MA ‡Department of Cardiology, Aultman Hospital, Canton Medical Education Foundation, Canton, Ohio. Received for publication September 11, 2019; accepted January 20, 2020. A.M. is supported by Research grants (Medtronic, Biotronik), Consulting fees (Medtronic), and Genetic AF trial, ARCA Biopharma. Reprints: Karuppiah Arunachalam, MD, Department of Cardiology Fellowship Program, Aultman Hospital, 2600 6th St SW, Canton, OH 44710. E-mail: Karuppiah.email@example.com. Critical Pathways in Cardiology: June 2020 - Volume 19 - Issue 2 - p 87-89 doi: 10.1097/HPC.0000000000000210 Buy Metrics Abstract Hypertrophic cardiomyopathy (HCM) is 1 of the most frequent genetic cardiovascular diseases affecting 1 out of every 500 individuals in general population. Atrial Fibrillation incidences were 3.8% per 100 patients per year and overall prevalence among HCM patients are 27.09%. Higher risk of death noted in HCM patients with atrial fibrillation. Stroke and other thrombo embolic risks are increased in such patients. Medical management using mainly betablockers or amiodarone produced variable results and high rate of recurrence. Catheter ablation reduced symptom burden and complications despite moderate recurrence. Patients with multiple repeated procedures found to have better success rate and outcomes. The complications are not high leading to increased feasibility of the procedure. More research using latest techniques in catheter ablation need to be studied. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.